SAFINAMIDE MESYLATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H19FN2O2.CH4O3S
Molecular Weight	398.449
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(O)(=O)=O.C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O

InChI

InChIKey=YKOCHIUQOBQIAC-YDALLXLXSA-N

InChI=1S/C17H19FN2O2.CH4O3S/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14;1-5(2,3)4/h2-9,12,20H,10-11H2,1H3,(H2,19,21);1H3,(H,2,3,4)/t12-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C17H19FN2O2
Molecular Weight	302.3434
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	CH4O3S
Molecular Weight	96.106
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17030736
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27536120 | http://adisinsight.springer.com/drugs/800009612

Safinamide (FCE 26743, NW 1015, PNU 151774, PNU 151774E, trade name Xadago) combines potent, selective, and reversible inhibition of MAO-B with blockade of voltage-dependent Na+ and Ca2+ channels and inhibition of glutamate release. Safinamide is under development with Newron, Zambon and Meiji Seika Pharma for the treatment of Parkinson's disease. Safinamide has been launched in the EU, Iceland and Liechtenstein. Safinamide was well tolerated and safe in the clinical development program that demonstrated the amelioration of motor symptoms and OFF phenomena by safinamide when combined with dopamine agonists or levodopa.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Monoamine oxidase B 75 Target ID: CHEMBL2039 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17824599	Inhibitor 8504	98.0 nM [IC50]
Sodium channel alpha subunit 72 Target ID: CHEMBL2331043 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10027853	Blocker 555	8.0 µM [IC50]
glutamate secretion 3 Target ID: GO:0014047 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10027853	Inhibitor 8504	56.4 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Parkinson's disease 232 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002396/WC500184965.pdf	Primary		Approved 8583	XADAGO Approved Use Xadago (safinamide) is indicated for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients. Launch Date 2015

C_max

Value	Dose	Co-administered	Analyte	Population
650 ng/mL OTHER GOV https://www.ema.europa.eu/en/documents/assessment-report/xadago-epar-public-assessment-report_en.pdf	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		SAFINAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
19000 ng × h/mL OTHER GOV https://www.ema.europa.eu/en/documents/assessment-report/xadago-epar-public-assessment-report_en.pdf	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		SAFINAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
26 h OTHER GOV https://www.ema.europa.eu/en/documents/assessment-report/xadago-epar-public-assessment-report_en.pdf	single, intravenous		SAFINAMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
11.5% OTHER GOV https://www.ema.europa.eu/en/documents/assessment-report/xadago-epar-public-assessment-report_en.pdf	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		SAFINAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
400 mg 1 times / day single, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: single Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24136086/	healthy, mean age 28.7 years Health Status: healthy Age Group: mean age 28.7 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/24136086/	Other AEs: Headache... Other AEs: Headache (grade 1, 16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/24136086/
350 mg 1 times / day multiple, oral Higher than recommended Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22948897/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	healthy, mean age 41.2 years Health Status: healthy Age Group: mean age 41.2 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/22948897/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	Other AEs: Diarrhea, Headache... Other AEs: Diarrhea (5.5%) Headache (5.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/22948897/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf
350 mg 1 times / day multiple, oral Higher than recommended Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22948897/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	healthy, mean age 41.2 years Health Status: healthy Age Group: mean age 41.2 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/22948897/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	Disc. AE: ALT increased... Other AEs: Palpitations, Nausea... AEs leading to discontinuation/dose reduction: ALT increased (5.5%) Other AEs: Palpitations (5.5%) Nausea (5.5%) Pharyngitis (5.5%) Headache (5.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/22948897/ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf
350 mg 1 times / day multiple, oral Higher than recommended Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000CrossR.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000CrossR.pdf	Other AEs: Headache, Dizziness... Other AEs: Headache (11.9%) Dizziness (5.1%) Nausea (3.4%) Nasopharyngitis (1.7%) Fatigue (3.4%) Vomiting (1.7%) Diarrhea (1.7%) Skin laceration (1.7%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000CrossR.pdf
100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	Disc. AE: Angina pectoris, Aortic valve incompetence... AEs leading to discontinuation/dose reduction: Angina pectoris (0.3%) Aortic valve incompetence (0.3%) Atrial flutter (0.3%) Creatine phosphokinase increased (0.3%) Vertigo (0.3%) Cataract (0.3%) Lacrimation increased (0.3%) Macular oedema (0.3%) Maculopathy (0.3%) Ocular vascular disorder (0.3%) Papilloedema (0.3%) Paraesthesia (0.3%) Pain of skin (0.3%) Rash erythematous (0.3%) Anaemia iron deficiency (0.3%) Depressed mood (0.3%) Bronchospasm (0.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf
100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	Disc. AE: Dyskinesia, Parkinson's disease... AEs leading to discontinuation/dose reduction: Dyskinesia (1.4%) Parkinson's disease (0.6%) Dizziness (0.2%) Paraesthesia (0.2%) Cognitive disorder (0.2%) Presyncope (0.2%) Abdominal pain (0.2%) Vomiting (0.2%) Hallucination, visual (0.6%) Hallucination (0.2%) Sleep terror (0.2%) Asthenia (0.2%) Muscle spasms (0.4%) Basal cell carcinoma (0.2%) Breast cancer (0.2%) Non-Hodgkin's lymphoma (0.2%) Arrhythmia (0.2%) Ventricular tachycardia (0.2%) Cataract subcapsular (0.2%) Vision blurred (0.2%) Change in ECG (0.2%) QT interval prolonged (0.2%) Blister (0.2%) Hyperhidrosis (0.2%) Fall (0.2%) Subdural haematoma (0.2%) Cachexia (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf
50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	Disc. AE: Swollen tongue, Dyspnea... AEs leading to discontinuation/dose reduction: Swollen tongue Dyspnea Redness mouth Gingival swelling Rash trunk Decreased appetite Increased appetite Inner restlessness Redness of face Pruritus Hyperhidrosis Dry mouth Hoarseness Malaise Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf
50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	Disc. AE: Myocardial infarction, Palpitations... AEs leading to discontinuation/dose reduction: Myocardial infarction (0.4%) Palpitations (0.4%) Ventricular tachycardia (0.4%) QT interval prolonged (0.9%) Blood glucose increased (0.4%) Vertigo (0.4%) Muscle spasms (0.4%) Tremor (0.4%) Nausea (0.4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf
50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	Disc. AE: Dyskinesia, Dizziness... AEs leading to discontinuation/dose reduction: Dyskinesia (1.3%) Dizziness (0.4%) Paraesthesia (0.4%) Balance disorder (0.4%) Tremor (0.4%) Abdominal pain (0.4%) Vomiting (0.4%) Aphthous stomatitis (0.4%) Constipation (0.4%) Nausea (0.4%) Asthenia (0.4%) Chest discomfort (0.4%) Muscle rigidity (0.4%) Dyspnoea (0.9%) Pneumonitis (0.4%) Palpitations (0.4%) Urinary tract infection (0.4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf
200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	Disc. AE: Head titubation, Nausea... AEs leading to discontinuation/dose reduction: Head titubation (1.1%) Nausea (2.2%) Diarrhea (1.1%) GERD (1.1%) Vomiting (1.1%) Anxiety (1.1%) Nightmare (1.1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inducer 1087	inhibitor 2438 inducer 440	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT2 779 OATP1B1 1079 OATP1B3 961 BSEP 550 BCRP 910 P-gp 1741 CYP2A6 879 CYP2B6 926 CYP2C8 1057 CYP2C19 2057 CYP2E1 1060 CYP3A4/5 296 CYP1A1 132 CYP1A2 2153 ALDH1 41	ALDH 6 P-gp 2052 UGT1A 7	CYP1A2 832 CYP2B6 669 UGT1A1 78 SULT2A1 4

Drug as perpetrator

Target	Modality	Activity	Metabolite
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=8 Page: 8.0	no [IC50 43 uM]
BSEP 554	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=8 Page: 8.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1153 3
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1689 3
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1153 3
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1689 3
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1153 3
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1689 3
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1153 3
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1689 3
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1153 3
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1689 3
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1153 3
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1689 3
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1153 3
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1689 3
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1153 3
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1689 3
CYP3A4/5 357	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no
CYP3A4/5 357	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1153 3
CYP3A4/5 357	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	no	NW-1689 3
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=8 Page: 8.0	no
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=8 Page: 8.0	no
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=8 Page: 8.0	no
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=8 Page: 8.0	no
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=37 Page: 37.0	no	NW-1153 3
SULT2A1 9	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=37 Page: 37.0	no
UGT1A1 303	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=37 Page: 37.0	no
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=8 Page: 8.0	yes [IC50 3.7 uM]	NW-1689 3
ALDH1 41	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=35 Page: 35.0	yes [IC50 35 uM]	NW-1689 3
CYP1A1 272	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	yes [IC50 47.7 uM]
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=37 Page: 37.0	yes
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=37 Page: 37.0	yes
CYP2C9 2497	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=37 Page: 37.0	yes
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=37 Page: 37.0	yes

Drug as victim

Target	Modality	Activity
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=7 Page: 7.0	minor
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=8 Page: 8.0	no
ALDH 6	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=7 Page: 7.0	yes
UGT1A 7	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000ClinPharmR.pdf#page=18 Page: 18.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000PharmR.pdf#page=42 Page: 42.0

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA0038VE	https://www.aablocks.com/goods/Goods/detail?id=AA0038VE
Aaron Chemicals	AR0039N6	http://www.aaronchem.com/133865-89-1
abcr GmbH	AB506034	http://www.abcr.com/shop/en/AB506034
Aceschem	ACF023692	https://www.aceschem.com/catalog/133865-89-1.html
Achemo Scientific Limited	AC-74101	http://www.achemo.com/search/?Keyword= 133865-89-1
Achemtek	0102-020052	http://www.achemtek.com/133865-89-1
Adooq BioScience	A13294	https://www.adooq.com/safinamide.html
AK Scientific, Inc. (AKSCI)	6135AA	http://www.aksci.com/item_detail.php?cat=6135AA
Alsachim	1719	http://www.alsachim.com/product-C2493-glo.bal-view.html
Ambeed	A189271	https://www.ambeed.com/products/133865-89-1.html
Annker Organics	P111001	http://www.annker.com/detailproe.php?id=10
Anward	ANW-58666	http://www.anward.com/pro_result/45117
ApexBio Technology	A3784	http://www.apexbt.com/safinamide.html
Aurora Fine Chemicals LLC	A24.076.620	http://online.aurorafinechemicals.com/info?ID=A24.076.620
Aurum Pharmatech LLC	W-5197	http://www.Aurumpharmatech.com/Product/ProductDetails/W_5197
AvaChem Scientific	6759	https://www.avachem.com/productSearch.asp?6759
BioChemPartner	BCP12082	http://www.biochempartner.com/133865-89-1-BCP12082
BioSynth	J-506604	https://www.biosynth.com/en/products/all-products/products/J-506604.html
BLD Pharm	BD150732	http://www.bldpharm.com/products/133865-89-1.html
Boerchem	BC224413	http://www.boerchem.com/?product_37818.html
Chem Scene	CS-0556	http://www.chemscene.com/133865-89-1.html
ChemMol	44007195	http://www.chemmol.com/chemmol/44007195.html
ChemMol	99041292	http://www.chemmol.com/chemmol/99041292.html
Chemspace	CSSB00016989084	https://chem-space.com/CSSB00016989084
CSNpharm	CSN11880	https://www.csnpharm.com/products/safinamide.html
DC Chemicals	DC4134	http://www.dcchemicals.com/product_show-Safinamide.html
Excenen	EX-A2759	https://www.excenen.com/searchresultlist.php?id=133865-89-1
Hairui	HR108800	http://www.hairuichem.com/en/product/133865-89-1.html
iChemical	EBD31483	http://www.ichemical.com/products/133865-89-1.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN01343308	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343308
Matrix Scientific	198643	https://www.matrixscientific.com/198643.html
MedChem Express	HY-70057	https://www.medchemexpress.com/Safinamide.html
MuseChem	I001294	https://www.musechem.com/product/I001294.html
Renno Tech	RL01540	http://www.rennotech.com/product_show.asp?id=1789
Smolecule	S542288	http://www.smolecule.com/products/s542288
Synblock Inc	SB16691	http://www.synblock.com/product/133865-89-1.html
TCI (Tokyo Chemical Industry)	S0935	http://www.tcichemicals.com/eshop/en/us/commodity/S0935/index.html
THE BioTek	bt-281161	https://www.thebiotek.com/product/inhibitors/bt-281161
Yuhao Chemical	LL2156	http://www.chemyuhao.com/133865-89-1.html

PubMed

Title	Date	PubMed
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.	2013-12-01	24139167
A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency.	2013-02-05	23386436
Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones.	2011-12-08	22017497
3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles: a new scaffold for the selective inhibition of monoamine oxidase B.	2011-09-22	21777011
Safinamide in the treatment of Parkinson's disease.	2010-09	20707760
Superpose3D: a local structural comparison program that allows for user-defined structure representations.	2010-08-05	20700534
The Movement Disorder Society--14th International Congress of Parkinson's Disease and Movement Disorders.	2010-08	20721824
Two polymorphs of safinamide, a selective and reversible inhibitor of monoamine oxidase B.	2010-06	20522954
Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs.	2010-04	20502724
An expert opinion on safinamide in Parkinson's disease.	2008-07	18549347
Computational systems analysis of dopamine metabolism.	2008-06-18	18568086
Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions.	2008-03-02	19443931
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.	2007-12	18041937
Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs.	2007-11-15	17915852
Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase.	2007-10-04	17824599
Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.	2007-07	17659477
Safinamide.	2007-01	17199024
New pharmacologic horizons in the treatment of Parkinson disease.	2006-10-10	17030738
Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition.	2006-10-10	17030737
Safinamide: from molecular targets to a new anti-Parkinson drug.	2006-10-10	17030736
Bioassay of safinamide in biological fluids of humans and various animal species.	2006	17260668
Voltage gated ion channels: targets for anticonvulsant drugs.	2005	15638775
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII).	2004-12-02	15570674
Improvement of motor function in early Parkinson disease by safinamide.	2004-08-24	15326260
Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.	2004-07	15082032
Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class.	2004-03-25	15027868
Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E.	2004	15563241
Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition.	2003-08-05	12897643
Novel anticonvulsant medications in development.	2002-10	12387702
Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI).	2002-09	12350382
Safinamide (Newron Pharmaceuticals).	2001-06	11572661
Future prospects for the drug treatment of epilepsy.	2001	11735615

Patents

Sample Use Guides

In Vivo Use Guide

Treatment with Xadago (Safinamide) should be started at 50 mg per day. This daily dose may be increased to 100 mg/day on the basis of individual clinical need.

Route of Administration: Oral

In Vitro Use Guide

Safinamide (PNU-151774E) reduces sustained repetitive firing in a use-dependent manner without modifying the first action potential in hippocampal cultured neurons. The inhibition of the currents by PNU-151774E was concentration-related from 10 to 200 μM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:32:48 GMT 2025` Edited by `admin` on `Mon Mar 31 18:32:48 GMT 2025`
Record UNII	YS90V3DTX0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SAFINAMIDE MESILATE

Preferred Name

English

SAFINAMIDE MESYLATE

Official Name

English

SAFINAMIDE METHANESULFONATE

Common Name

English

XADAGO

Brand Name

English

(S)-2-((4-((3-FLUOROBENZYL)OXY)BENZYL)AMINO)PROPANAMIDE METHANESULFONATE

Systematic Name

English

SAFINAMIDE MESYLATE [ORANGE BOOK]

Common Name

English

NW-1015

Code

English

PNU 151774E

Code

English

NW 1015

Code

English

PNU-151774E

Code

English

SAFINAMIDE MESILATE [JAN]

Common Name

English

SAFINAMIDE METHANESULFONATE [MI]

Common Name

English

SAFINAMIDE MESYLATE [USAN]

Common Name

English

Safinamide mesilate [WHO-DD]

Common Name

English

SAFINAMIDE METHANSULFONATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C264